Biomarkers of inflammation and amyloid-β phagocytosis in patients at risk of Alzheimer disease

Experimental Gerontology

Volumn 45, Issue 1, 2010, Pages 57-63

  Fiala, Milan ^a   Veerhuis, Robert ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Alzheimer disease biomarkers; Amyloid beta; Astrocyte; Complement; Inflammation; Macrophage; Microglia; Neuron; Phagocytosis; Serum amyloid P

Indexed keywords

AMYLOID BETA PROTEIN; ANTIINFLAMMATORY AGENT; CHEMOKINE; COMPLEMENT; CYTOKINE; IMMUNOSTIMULATING AGENT; TRANSCRIPTOME;

ALZHEIMER DISEASE; APOPTOSIS; ASTROCYTE; BLOOD ANALYSIS; CELL DIFFERENTIATION; CELL FUNCTION; CELL STRESS; CEREBROSPINAL FLUID EXAMINATION; CLINICAL TRIAL; DEGENERATIVE DISEASE; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DISEASE COURSE; DISEASE MARKER; FLOW CYTOMETRY; HUMAN; IMMUNOLOGICAL PROCEDURES; MACROPHAGE FUNCTION; MICROGLIA; NERVE CELL LESION; NERVOUS SYSTEM INFLAMMATION; NEUROFIBRILLARY TANGLE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEOMICS; REVIEW; SENSITIVITY AND SPECIFICITY;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BIOLOGICAL MARKERS; HUMANS; INFLAMMATION; MACROPHAGES; MICROGLIA; PHAGOCYTOSIS; RISK FACTORS;

EID: 71849103796     PISSN: 05315565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exger.2009.08.003     Document Type: Review

References (44)

1. Abdi F., Quinn J.F., Jankovic J., McIntosh M., Leverenz J.B., Peskind E., Nixon R., Nutt J., Chung K., Zabetian C., Samii A., Lin M., Hattan S., Pan C., Wang Y., Jin J., Zhu D., Li G.J., Liu Y., Waichunas D., Montine T.J., and Zhang J. Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J. Alzheimers Dis. 9 (2006) 293-348
2. Akiyama H., Barger S., Barnum S., Bradt B., Bauer J., Cole G.M., Cooper N.R., Eikelenboom P., Emmerling M., Fiebich B.L., Finch C.E., Frautschy S., Griffin W.S., Hampel H., Hull M., Landreth G., Lue L., Mrak R., Mackenzie I.R., McGeer P.L., O'Banion M.K., Pachter J., Pasinetti G., Plata-Salaman C., Rogers J., Rydel R., Shen Y., Streit W., Strohmeyer R., Tooyoma I., Van Muiswinkel F.L., Veerhuis R., Walker D., Webster S., Wegrzyniak B., Wenk G., and Wyss-Coray T. Inflammation and Alzheimer's disease. Neurobiol. Aging 21 (2000) 383-421
3. Avagyan H., Goldenson B., Tse E., Masoumi A., Porter V., Wiedau-Pazos M., Sayre J., Ong R., Mahanian M., Koo P., Bae S., Micic M., Liu P.T., Rosenthal M.J., and Fiala M. Immune blood biomarkers of Alzheimer disease patients. J. Neuroimmunol. 210 (2009) 67-72
4. Blennow K., and Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol. 2 (2003) 605-613
5. Boland B., Kumar A., Lee S., Platt F.M., Wegiel J., Yu W.H., and Nixon R.A. Autophagy induction and autophagosome clearance in neurons: relationship to autophagic pathology in Alzheimer's disease. J. Neurosci. 28 (2008) 6926-6937
6. Carro E., Spuch C., Trejo J.L., Antequera D., and Torres-Aleman I. Choroid plexus megalin is involved in neuroprotection by serum insulin-like growth factor I. J. Neurosci. 25 (2005) 10884-10893
7. Colangelo V., Schurr J., Ball M.J., Pelaez R.P., Bazan N.G., and Lukiw W.J. Gene expression profiling of 12633 genes in Alzheimer hippocampal CA1: transcription and neurotrophic factor down-regulation and up-regulation of apoptotic and pro-inflammatory signaling. J. Neurosci. Res. 70 (2002) 462-473
8. Colton C.A., Mott R.T., Sharpe H., Xu Q., Van Nostrand W.E., and Vitek M.P. Expression profiles for macrophage alternative activation genes in AD and in mouse models of AD. J. Neuroinflammation 3 (2006) 27
9. Craig-Schapiro R., Fagan A.M., and Holtzman D.M. Biomarkers of Alzheimer's disease. Neurobiol Dis. 35 (2009) 128-140
10. de Leon M.J., Mosconi L., Li J., De Santi S., Yao Y., Tsui W.H., Pirraglia E., Rich K., Javier E., Brys M., Glodzik L., Switalski R., Saint Louis L.A., and Pratico D. Longitudinal CSF isoprostane and MRI atrophy in the progression to AD. J. Neurol. 254 (2007) 1666-1675
11. Deane R., Bell R.D., Sagare A., and Zlokovic B.V. Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease. CNS Neurol. Disord. Drug Targets 8 (2009) 16-30
12. Eikelenboom P., and Veerhuis R. The role of complement and activated microglia in the pathogenesis of Alzheimer's disease. Neurobiol. Aging 17 (1996) 673-680
13. Fagan A.M., Head D., Shah A.R., Marcus D., Mintun M., Morris J.C., and Holtzman D.M. Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann. Neurol. 65 (2009) 176-183
14. Fagan A.M., Roe C.M., Xiong C., Mintun M.A., Morris J.C., and Holtzman D.M. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch. Neurol. 64 (2007) 343-349
15. Familian A., Eikelenboom P., and Veerhuis R. Minocycline does not affect amyloid beta phagocytosis by human microglial cells. Neurosci. Lett. 416 (2007) 87-91
16. Fiala M., Lin J., Ringman J., Kermani-Arab V., Tsao G., Patel A., Lossinsky A.S., Graves M.C., Gustavson A., Sayre J., Sofroni E., Suarez T., Chiappelli F., and Bernard G. Ineffective phagocytosis of amyloid-beta by macrophages of Alzheimer's disease patients, discussion 255-262. J. Alzheimers Dis. 7 (2005) 221-232
17. Fiala M., Liu N.Q., Reddy S., and Graves M.C. Macrophages infiltrate brain and express COX-2 and iNOS in Alzheimer's disease and AIDS. Alzheimer's Reports 4 (2001) 1-7
18. Fiala M., Liu P.T., Espinosa-Jeffrey A., Rosenthal M.J., Bernard G., Ringman J.M., Sayre J., Zhang L., Zaghi J., Dejbakhsh S., Chiang B., Hui J., Mahanian M., Baghaee A., Hong P., and Cashman J. Innate immunity and transcription of MGAT-III and Toll-like receptors in Alzheimer's disease patients are improved by bisdemethoxycurcumin. Proc. Natl. Acad. Sci. USA 104 (2007) 12849-12854
19. Fiala M., Liu Q.N., Sayre J., Pop V., Brahmandam V., Graves M.C., and Vinters H.V. Cyclooxygenase-2-positive macrophages infiltrate the Alzheimer's disease brain and damage the blood-brain barrier. Eur. J. Clin. Invest. 32 (2002) 360-371
20. Fox N.C., Black R.S., Gilman S., Rossor M.N., Griffith S.G., Jenkins L., and Koller M. Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 64 (2005) 1563-1572
21. Hoozemans J.J., van Haastert E.S., Veerhuis R., Arendt T., Scheper W., Eikelenboom P., and Rozemuller A.J. Maximal COX-2 and ppRb expression in neurons occurs during early Braak stages prior to the maximal activation of astrocytes and microglia in Alzheimer's disease. J. Neuroinflammation 2 (2005) 27
22. Hoozemans J.J., Veerhuis R., Rozemuller J.M., and Eikelenboom P. Neuroinflammation and regeneration in the early stages of Alzheimer's disease pathology. Int. J. Dev. Neurosci. 24 (2006) 157-165
23. Hye A., Lynham S., Thambisetty M., Causevic M., Campbell J., Byers H.L., Hooper C., Rijsdijk F., Tabrizi S.J., Banner S., Shaw C.E., Foy C., Poppe M., Archer N., Hamilton G., Powell J., Brown R.G., Sham P., Ward M., and Lovestone S. Proteome-based plasma biomarkers for Alzheimer's disease. Brain 129 (2006) 3042-3050
24. Killiany R.J., Gomez-Isla T., Moss M., Kikinis R., Sandor T., Jolesz F., Tanzi R., Jones K., Hyman B.T., and Albert M.S. Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease. Ann. Neurol. 47 (2000) 430-439
25. Kolstoe S.E., Ridha B.H., Bellotti V., Wang N., Robinson C.V., Crutch S.J., Keir G., Kukkastenvehmas R., Gallimore J.R., Hutchinson W.L., Hawkins P.N., Wood S.P., Rossor M.N., and Pepys M.B. Molecular dissection of Alzheimer's disease neuropathology by depletion of serum amyloid P component. Proc. Natl. Acad. Sci. USA 106 (2009) 7619-7623
26. Kusdra L., Rempel H., Yaffe K., and Pulliam L. Elevation of CD69+ monocyte/macrophages in patients with Alzheimer's disease [In Process Citation]. Immunobiology 202 (2000) 26-33
27. Masoumi A., Goldenson B., Ghirmai S., Avagyan H., Zaghi J., Abel K., Zheng X., Espinosa-Jeffrey A., Mahanian M., Liu P.T., Hewison M., Mizwicki M., Cashman J., and Fiala M. 1alpha,25-dihydroxyvitamin D3 Interacts with Curcuminoids to Stimulate Amyloid-beta Clearance by Macrophages of Alzheimer's Disease Patients. J Alzheimers Dis. 17 (2009) 703-717
28. Morelli L., Bulloj A., Leal M.C., and Castano E.M. Amyloid beta degradation: a challenging task for brain peptidases. Subcell Biochem. 38 (2005) 129-145
29. Nielsen H.M., Veerhuis R., Holmqvist B., and Janciauskiene S. Binding and uptake of A beta1-42 by primary human astrocytes in vitro. Glia 57 (2009) 978-988
30. Ray S., Britschgi M., Herbert C., Takeda-Uchimura Y., Boxer A., Blennow K., Friedman L.F., Galasko D.R., Jutel M., Karydas A., Kaye J.A., Leszek J., Miller B.L., Minthon L., Quinn J.F., Rabinovici G.D., Robinson W.H., Sabbagh M.N., So Y.T., Sparks D.L., Tabaton M., Tinklenberg J., Yesavage J.A., Tibshirani R., and Wyss-Coray T. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat. Med. 13 (2007) 1359-1362
31. Riley K.P., Snowdon D.A., Desrosiers M.F., and Markesbery W.R. Early life linguistic ability, late life cognitive function, and neuropathology: findings from the Nun Study. Neurobiol. Aging 26 (2005) 341-347
32. Rota E., Bellone G., Rocca P., Bergamasco B., Emanuelli G., and Ferrero P. Increased intrathecal TGF-beta1, but not IL-12, IFN-gamma and IL-10 levels in Alzheimer's disease patients. Neurol. Sci. 27 (2006) 33-39
33. Schoonenboom N.S., van der Flier W.M., Blankenstein M.A., Bouwman F.H., Van Kamp G.J., Barkhof F., and Scheltens P. CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease. Neurobiol. Aging 29 (2008) 669-675
34. Schuitemaker, A., Dik, M.G., Veerhuis, R., Scheltens, P., Schoonenboom, N.S., Hack, C.E., Blankenstein, M.A., Jonker, C., 2008. Inflammatory markers in AD and MCI patients with different biomarker profiles. Neurobiol. Aging. doi:10.1016/j.neurobiolaging.2008.01.014.
35. Simonsen A.H., McGuire J., Hansson O., Zetterberg H., Podust V.N., Davies H.A., Waldemar G., Minthon L., and Blennow K. Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment. Arch. Neurol. 64 (2007) 366-370
36. Sunderland T., Linker G., Mirza N., Putnam K.T., Friedman D.L., Kimmel L.H., Bergeson J., Manetti G.J., Zimmermann M., Tang B., Bartko J.J., and Cohen R.M. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 289 (2003) 2094-2103
37. Tarkowski E., Andreasen N., Tarkowski A., and Blennow K. Intrathecal inflammation precedes development of Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 74 (2003) 1200-1205
38. Veerhuis R., Boshuizen R.S., and Familian A. Amyloid associated proteins in Alzheimer's and prion disease. Curr. Drug Targets CNS Neurol. Disord. 4 (2005) 235-248
39. Verwey N.A., Schuitemaker A., van der Flier W.M., Mulder S.D., Mulder C., Hack C.E., Scheltens P., Blankenstein M.A., and Veerhuis R. Serum amyloid p component as a biomarker in mild cognitive impairment and Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 26 (2008) 522-527
40. Walter S., Letiembre M., Liu Y., Heine H., Penke B., Hao W., Bode B., Manietta N., Walter J., Schulz-Schuffer W., and Fassbender K. Role of the toll-like receptor 4 in neuroinflammation in Alzheimer's disease. Cell Physiol. Biochem 20 6 (2007) 947-956
41. Wilhelmus M.M., Otte-Holler I., van Triel J.J., Veerhuis R., Maat-Schieman M.L., Bu G., de Waal R.M., and Verbeek M.M. Lipoprotein receptor-related protein-1 mediates amyloid-beta-mediated cell death of cerebrovascular cells. Am. J. Pathol. 171 (2007) 1989-1999
42. Zaghi J., Goldenson B., Inayathullah M., Lossinsky A.S., Masoumi A., Avagyan H., Mahanian M., Bernas M., Weinand M., Rosenthal M.J., Espinosa-Jeffrey A., de Vellis J., Teplow D.B., and Fiala M. Alzheimer disease macrophages shuttle amyloid-beta from neurons to vessels, contributing to amyloid angiopathy. Acta Neuropathol. 117 (2009) 111-124
43. Zetterberg H., Ruetschi U., Portelius E., Brinkmalm G., Andreasson U., Blennow K., and Brinkmalm A. Clinical proteomics in neurodegenerative disorders. Acta Neurol. Scand. 118 (2008) 1-11
44. Zhao L., Lin S., Bales K.R., Gelfanova V., Koger D., Delong C., Hale J., Liu F., Hunter J.M., and Paul S.M. Macrophage-mediated degradation of beta-amyloid via an apolipoprotein E isoform-dependent mechanism. J. Neurosci. 29 (2009) 3603-3612